- Home
- TRU vs EXEL Comparison
TRU vs EXEL Comparison
Compare TRU & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | EXEL |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 11.4B |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TRU | EXEL |
|---|---|---|
| Price | $66.51 | $53.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $90.73 | $46.50 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 60.00 | 57.95 |
| EPS | ★ 2.04 | 0.79 |
| Revenue | ★ $4,576,300,000.00 | $452,477,000.00 |
| Revenue This Year | $11.20 | $13.61 |
| Revenue Next Year | $8.00 | $13.13 |
| P/E Ratio | ★ $33.26 | $66.72 |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $64.51 | $33.76 |
| 52 Week High | $99.39 | $53.82 |
Technical Indicators
Market Signals| Indicator | TRU | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 63.87 |
| Support Level | $65.84 | $40.17 |
| Resistance Level | $74.19 | N/A |
| Average True Range (ATR) | 2.53 | 1.54 |
| MACD | -0.37 | 0.10 |
| Stochastic Oscillator | 16.12 | 93.98 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion, along with Equifax and Experian, is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.